These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 20821397)

  • 21. Physical chemical considerations of lipid-based oral drug delivery--solid lipid nanoparticles.
    Bummer PM
    Crit Rev Ther Drug Carrier Syst; 2004; 21(1):1-20. PubMed ID: 15099183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of formulation composition and process on the characteristics and in vitro release from PLGA-based sustained release injectables.
    Meeus J; Scurr DJ; Appeltans B; Amssoms K; Annaert P; Davies MC; Roberts CJ; Van den Mooter G
    Eur J Pharm Biopharm; 2015 Feb; 90():22-9. PubMed ID: 25448071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The solid-state continuum: a perspective on the interrelationships between different solid-state forms in drug substance and drug product.
    Elder DP; Patterson JE; Holm R
    J Pharm Pharmacol; 2015 Jun; 67(6):757-72. PubMed ID: 25124049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A less irritant norcantharidin lipid microspheres: formulation and drug distribution.
    Lixin W; Haibing H; Xing T; Ruiying S; Dawei C
    Int J Pharm; 2006 Oct; 323(1-2):161-7. PubMed ID: 16828998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A preformulation evaluation of a photosensitive surface active compound, explaining concentration dependent degradation.
    Sigfridsson K; Carlsson KE
    Eur J Pharm Sci; 2017 Nov; 109():650-656. PubMed ID: 28736127
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs.
    Kawakami K
    Adv Drug Deliv Rev; 2012 May; 64(6):480-95. PubMed ID: 22265844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Survival of the Fittest: Time-To-Event Modeling of Crystallization of Amorphous Poorly Soluble Drugs.
    Nurzyńska K; Austin RP; Fischer PM; Booth J; Gommer F
    J Pharm Sci; 2016 Jun; 105(6):1858-1866. PubMed ID: 27238485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
    Kawabata Y; Wada K; Nakatani M; Yamada S; Onoue S
    Int J Pharm; 2011 Nov; 420(1):1-10. PubMed ID: 21884771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High drug loading self-microemulsifying/micelle formulation: design by high-throughput formulation screening system and in vivo evaluation.
    Sakai K; Obata K; Yoshikawa M; Takano R; Shibata M; Maeda H; Mizutani A; Terada K
    Drug Dev Ind Pharm; 2012 Oct; 38(10):1254-61. PubMed ID: 22339057
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-Term Amorphous Drug Stability Predictions Using Easily Calculated, Predicted, and Measured Parameters.
    Nurzyńska K; Booth J; Roberts CJ; McCabe J; Dryden I; Fischer PM
    Mol Pharm; 2015 Sep; 12(9):3389-98. PubMed ID: 26236939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Solubility and dissolution enhancement strategies: current understanding and recent trends.
    Jain S; Patel N; Lin S
    Drug Dev Ind Pharm; 2015 Jun; 41(6):875-87. PubMed ID: 25342479
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of solid state properties on developability assessment of drug candidates.
    Huang LF; Tong WQ
    Adv Drug Deliv Rev; 2004 Feb; 56(3):321-34. PubMed ID: 14962584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Physicochemical characterization of cyclodextrin-drug interactions in the solid state and the effect of water on these interactions.
    Ogawa N; Takahashi C; Yamamoto H
    J Pharm Sci; 2015 Mar; 104(3):942-54. PubMed ID: 25581322
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of polymers on dissolution performance of an amorphous gelleable drug from surface-coated beads.
    Fan C; Pai-Thakur R; Phuapradit W; Zhang L; Tian H; Malick W; Shah N; Kislalioglu MS
    Eur J Pharm Sci; 2009 Apr; 37(1):1-10. PubMed ID: 19027852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of drug physical form during granulation, tabletting and storage.
    Williams AC; Cooper VB; Thomas L; Griffith LJ; Petts CR; Booth SW
    Int J Pharm; 2004 May; 275(1-2):29-39. PubMed ID: 15081136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel furosemide cocrystals and selection of high solubility drug forms.
    Goud NR; Gangavaram S; Suresh K; Pal S; Manjunatha SG; Nambiar S; Nangia A
    J Pharm Sci; 2012 Feb; 101(2):664-80. PubMed ID: 22081478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integration of active pharmaceutical ingredient solid form selection and particle engineering into drug product design.
    Ticehurst MD; Marziano I
    J Pharm Pharmacol; 2015 Jun; 67(6):782-802. PubMed ID: 25677227
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmaceutical cocrystals: the coming wave of new drug substances.
    Brittain HG
    J Pharm Sci; 2013 Feb; 102(2):311-7. PubMed ID: 23192888
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Manufacturing of solid dispersions of poorly water soluble drugs by spray drying: formulation and process considerations.
    Paudel A; Worku ZA; Meeus J; Guns S; Van den Mooter G
    Int J Pharm; 2013 Aug; 453(1):253-84. PubMed ID: 22820134
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Investigation of solubilising effects of bile salts on an active pharmaceutical ingredient with unusual pH dependent solubility by NMR spectroscopy.
    Vogtherr M; Marx A; Mieden AC; Saal C
    Eur J Pharm Biopharm; 2015 May; 92():32-41. PubMed ID: 25720817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.